Eisai Co., Ltd.: Esophagitis, Peptic trials

The registry lists 11 Esophagitis, Peptic studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 2Phase 3 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease PatientsCompletedNCT02135107Phase 3Results posted
• Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)CompletedNCT00911534Phase 3Results posted
• Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00838526Phase 3Results posted
• Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux EsophagitisCompletedNCT00770913Phase 2/3Results posted
• Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658775Phase 3Results posted
• Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658632Phase 3Results posted
• Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658528Phase 3Results posted
• A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux DiseaseCompletedNCT00165672Phase 3Results posted
• A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseCompletedNCT00165646Phase 3Results posted
• Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleCompletedNCT00132496Phase 2Results posted
• Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux EsophagitisCompletedNCT01321567